DMK Pharmaceuticals Corporation
DMKPQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $4,756 | $2,209 | $2,777 | $22,114 |
| % Growth | 115.3% | -20.5% | -87.4% | – |
| Cost of Goods Sold | $7,654 | $6,872 | $6,327 | $15,679 |
| Gross Profit | -$2,898 | -$4,663 | -$3,550 | $6,435 |
| % Margin | -60.9% | -211.1% | -127.9% | 29.1% |
| R&D Expenses | $10,380 | $11,262 | $8,040 | $11,028 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11,781 | $16,144 | $20,090 | $25,088 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $322 |
| Operating Expenses | $22,161 | $27,406 | $28,129 | $36,438 |
| Operating Income | -$25,059 | -$32,069 | -$31,680 | -$30,003 |
| % Margin | -526.9% | -1,452% | -1,141% | -135.7% |
| Other Income/Exp. Net | -$1,138 | -$2,530 | -$4,164 | $1,195 |
| Pre-Tax Income | -$26,197 | -$34,600 | -$35,844 | -$28,156 |
| Tax Expense | $2 | $1 | $2 | -$643 |
| Net Income | -$26,478 | -$45,828 | -$49,391 | -$27,513 |
| % Margin | -556.7% | -2,074.9% | -1,778.8% | -124.4% |
| EPS | -12.37 | -22.25 | -44.57 | -36.16 |
| % Growth | 44.4% | 50.1% | -23.3% | – |
| EPS Diluted | -12.37 | -22.25 | -44.57 | -36.16 |
| Weighted Avg Shares Out | 2,141 | 2,059 | 1,108 | 761 |
| Weighted Avg Shares Out Dil | 2,141 | 2,059 | 1,108 | 761 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44 | $0 | $0 | $0 |
| Interest Expense | $0 | $7 | $5 | $123 |
| Depreciation & Amortization | $1,466 | $1,430 | $2,333 | $2,963 |
| EBITDA | -$23,575 | -$30,634 | -$33,506 | -$25,070 |
| % Margin | -495.7% | -1,387% | -1,206.7% | -113.4% |